Updated Results From the MajesTEC-1 Trial of Teclistamab

Findings from phase II of the phase I/II MajesTEC-1 study on teclistamab were presented for the first time at the 2021 Annual Meeting & Exposition of the American Society of Hematology (ASH), along with updated data from the phase I portion. According to the study’s lead author, Phillipe Moreau, MD, from the Hematology Clinic at … Continue reading Updated Results From the MajesTEC-1 Trial of Teclistamab